Compare Heron Therapeutics Inc (HRTX) vs Snap On Incorporated (SNA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Heron Therapeutics Inc vs Snap On Incorporated — how do they compare? Heron Therapeutics Inc trades at $0.47 (market cap $91.46M), while Snap On Incorporated trades at $408.6 (market cap $21.06B). The key difference: Snap On Incorporated is far larger — about 230.3× Heron Therapeutics Inc's market cap, and Snap On Incorporated pays a 2.4% dividend while Heron Therapeutics Inc pays none. Which is the better fit depends on your goals.
| HRTX | SNA | |
|---|---|---|
Market Cap | $91.46M | $21.06B |
Sector | Health | Technology |
52-Week High | $1.96 | $414.97 |
52-Week Low | $0.39 | $317.79 |
Enterprise Value | $189.36M | $20.58B |
Dividend Yield | — | 2.4% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
HRTX trades at $0.4804, up 2.06% today, with a bullish technical signal despite mixed earnings. The stock shows a low price-to-sales ratio of 0.51 but negative profitability, with a net income margin of -20.53% in 2026. Recent Q1 2026 earnings missed expectations, though management reaffirmed full-year guidance. Analyst consensus is strongly bullish with 94.7% buy ratings.
Outlook remains speculative given persistent losses and cash burn, but potential upside exists if operational improvements materialize. Key risks include patent litigation outcomes and reliance on revenue growth to achieve profitability. Investors should weigh high analyst optimism against fundamental challenges.
Snap-on Incorporated (SNA) trades at $406.53, down 1.09% on the day, near the consensus price target of $407.50. The stock shows a bullish technical trend with strong moving average signals and support at $403. Fundamentally, SNA maintains robust profitability with a 19.6% net income margin and 17.83% ROE, though Q1 2026 EPS slightly missed expectations. Recent acquisitions like Diesel Laptops for $100 million highlight strategic growth initiatives.
Outlook remains positive with 65% analyst buy ratings and a dividend yield supported by consistent cash flow. Key risks include margin pressures and muted revenue growth. The upcoming Q2 2026 earnings report on July 23, 2026, will be critical for validating current valuation multiples amid economic uncertainty.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Heron Therapeutics Inc
Heron Therapeutics is a commercial-stage biotechnology company focused on improving patient care. It develops best-in-class medicines for pain management and cancer care to address unmet medical needs.
Read more on HRTX →About Snap On Incorporated
Snap-on Incorporated is a leading global innovator, manufacturer, and marketer of tools, equipment, diagnostics, repair information, and systems solutions for professional users. Its products are widely used in vehicle service and repair, as well as in other demanding industrial environments. The company is best known for its premium tool brand, often sold through a network of franchised mobile stores, and is a primary supplier to technicians in the transportation industry.
Read more on SNA →
